Literature DB >> 29268098

Cholinergic Projections to the Substantia Nigra Pars Reticulata Inhibit Dopamine Modulation of Basal Ganglia through the M4 Muscarinic Receptor.

Mark S Moehle1, Tristano Pancani1, Nellie Byun2, Samantha E Yohn1, George H Wilson2, Johnathan W Dickerson1, Daniel H Remke1, Zixiu Xiang1, Colleen M Niswender3, Jürgen Wess4, Carrie K Jones1, Craig W Lindsley1, Jerri M Rook1, P Jeffrey Conn5.   

Abstract

Cholinergic regulation of dopaminergic inputs into the striatum is critical for normal basal ganglia (BG) function. This regulation of BG function is thought to be primarily mediated by acetylcholine released from cholinergic interneurons (ChIs) acting locally in the striatum. We now report a combination of pharmacological, electrophysiological, optogenetic, chemogenetic, and functional magnetic resonance imaging studies suggesting extra-striatal cholinergic projections from the pedunculopontine nucleus to the substantia nigra pars reticulata (SNr) act on muscarinic acetylcholine receptor subtype 4 (M4) to oppose cAMP-dependent dopamine receptor subtype 1 (D1) signaling in presynaptic terminals of direct pathway striatal spiny projections neurons. This induces a tonic inhibition of transmission at direct pathway synapses and D1-mediated activation of motor activity. These studies provide important new insights into the unique role of M4 in regulating BG function and challenge the prevailing hypothesis of the centrality of striatal ChIs in opposing dopamine regulation of BG output.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29268098      PMCID: PMC5753765          DOI: 10.1016/j.neuron.2017.12.008

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  72 in total

1.  Multiple muscarinic acetylcholine receptor subtypes modulate striatal dopamine release, as studied with M1-M5 muscarinic receptor knock-out mice.

Authors:  Weilie Zhang; Masahisa Yamada; Jesus Gomeza; Anthony S Basile; Jürgen Wess
Journal:  J Neurosci       Date:  2002-08-01       Impact factor: 6.167

2.  The experimental evaluation of antiparkinsonian compounds.

Authors:  K R UNNA; V G VERNIER
Journal:  Ann N Y Acad Sci       Date:  1956-11-16       Impact factor: 5.691

Review 3.  Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions.

Authors:  G E Alexander; M D Crutcher; M R DeLong
Journal:  Prog Brain Res       Date:  1990       Impact factor: 2.453

4.  Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies.

Authors:  A I Levey; C A Kitt; W F Simonds; D L Price; M R Brann
Journal:  J Neurosci       Date:  1991-10       Impact factor: 6.167

Review 5.  Acetylcholine-dopamine balance hypothesis in the striatum: an update.

Authors:  Toshihiko Aosaki; Masami Miura; Takeo Suzuki; Kinya Nishimura; Masao Masuda
Journal:  Geriatr Gerontol Int       Date:  2010-07       Impact factor: 2.730

Review 6.  Muscarinic acetylcholine receptors: novel opportunities for drug development.

Authors:  Andrew C Kruse; Brian K Kobilka; Dinesh Gautam; Patrick M Sexton; Arthur Christopoulos; Jürgen Wess
Journal:  Nat Rev Drug Discov       Date:  2014-06-06       Impact factor: 84.694

7.  Temporal and spatial characteristics of tonically active neurons of the primate's striatum.

Authors:  T Aosaki; M Kimura; A M Graybiel
Journal:  J Neurophysiol       Date:  1995-03       Impact factor: 2.714

Review 8.  Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders.

Authors:  P Jeffrey Conn; Carrie K Jones; Craig W Lindsley
Journal:  Trends Pharmacol Sci       Date:  2009-02-07       Impact factor: 14.819

Review 9.  Local control of striatal dopamine release.

Authors:  Roger Cachope; Joseph F Cheer
Journal:  Front Behav Neurosci       Date:  2014-05-23       Impact factor: 3.558

Review 10.  Anticholinergics for symptomatic management of Parkinson's disease.

Authors:  R Katzenschlager; C Sampaio; J Costa; A Lees
Journal:  Cochrane Database Syst Rev       Date:  2003
View more
  16 in total

Review 1.  Dichotomy between motor and cognitive functions of midbrain cholinergic neurons.

Authors:  Nadine K Gut; Juan Mena-Segovia
Journal:  Neurobiol Dis       Date:  2018-09-10       Impact factor: 5.996

2.  Novel M4 positive allosteric modulators derived from questioning the role and impact of a presumed intramolecular hydrogen-bonding motif in β-amino carboxamide-harboring ligands.

Authors:  Michael S Poslusney; James M Salovich; Michael R Wood; Bruce J Melancon; Katrina A Bollinger; Vincent B Luscombe; Alice L Rodriguez; Darren W Engers; Thomas M Bridges; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2018-12-18       Impact factor: 2.823

3.  Tyrosine Hydroxylase Inhibition in Substantia Nigra Decreases Movement Frequency.

Authors:  Michael F Salvatore; Tamara R McInnis; Mark A Cantu; Deana M Apple; Brandon S Pruett
Journal:  Mol Neurobiol       Date:  2018-07-28       Impact factor: 5.590

Review 4.  Roles of the M4 acetylcholine receptor in the basal ganglia and the treatment of movement disorders.

Authors:  Mark S Moehle; P Jeffrey Conn
Journal:  Mov Disord       Date:  2019-06-18       Impact factor: 10.338

5.  Multineuromodulator measurements across fronto-striatal network areas of the behaving macaque using solid-phase microextraction.

Authors:  Seyed-Alireza Hassani; Sofia Lendor; Ezel Boyaci; Janusz Pawliszyn; Thilo Womelsdorf
Journal:  J Neurophysiol       Date:  2019-08-21       Impact factor: 2.714

6.  SAR inspired by aldehyde oxidase (AO) metabolism: Discovery of novel, CNS penetrant tricyclic M4 PAMs.

Authors:  Trevor C Chopko; Changho Han; Alison R Gregro; Darren W Engers; Andrew S Felts; Mike S Poslusney; Katrina A Bollinger; Ryan D Morrison; Michael Bubser; Atin Lamsal; Vincent B Luscombe; Hyekyung P Cho; Nathalie C Schnetz-Boutaud; Alice L Rodriguez; Sichen Chang; J Scott Daniels; Donald F Stec; Colleen M Niswender; Carrie K Jones; Michael R Wood; Michael W Wood; Mark E Duggan; Nicholas J Brandon; P Jeffrey Conn; Thomas M Bridges; Craig W Lindsley; Bruce J Melancon
Journal:  Bioorg Med Chem Lett       Date:  2019-06-20       Impact factor: 2.823

Review 7.  Targeting Muscarinic Acetylcholine Receptors for the Treatment of Psychiatric and Neurological Disorders.

Authors:  Sean P Moran; James Maksymetz; P Jeffrey Conn
Journal:  Trends Pharmacol Sci       Date:  2019-11-08       Impact factor: 14.819

Review 8.  Targeting muscarinic receptors to treat schizophrenia.

Authors:  Daniel J Foster; Zoey K Bryant; P Jeffrey Conn
Journal:  Behav Brain Res       Date:  2021-02-26       Impact factor: 3.332

9.  Discovery of the First Selective M4 Muscarinic Acetylcholine Receptor Antagonists with in Vivo Antiparkinsonian and Antidystonic Efficacy.

Authors:  Mark S Moehle; Aaron M Bender; Jonathan W Dickerson; Daniel J Foster; Aidong Qi; Hyekyung P Cho; Yuping Donsante; Weimin Peng; Zoey Bryant; Kaylee J Stillwell; Thomas M Bridges; Sichen Chang; Katherine J Watson; Jordan C O'Neill; Julie L Engers; Li Peng; Alice L Rodriguez; Colleen M Niswender; Craig W Lindsley; Ellen J Hess; P Jeffrey Conn; Jerri M Rook
Journal:  ACS Pharmacol Transl Sci       Date:  2021-08-02

Review 10.  Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms.

Authors:  Robert A McCutcheon; Anissa Abi-Dargham; Oliver D Howes
Journal:  Trends Neurosci       Date:  2019-01-06       Impact factor: 13.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.